A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects

NCT ID: NCT04453618

Last Updated: 2020-07-01

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-31
• Study Completion Date: 2020-12-31

Brief Summary

A Multiple Doses Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Including Food Effect) of SYHA1402 in Healthy Subjects.

Detailed Description

This study consists of two parts: The objective of the food effect study (Part 1) is to investigate the effect of food on the pharmacokinetic profiles of SYHA1402 tablets under fed and fasted conditions following the oral administration of SYHA1402.

The primary objective of the multiple doses study (Part 2) is to investigate safety, tolerability and Pharmacokinetics of SYHA1402 in healthy subjects following oral administration of Multiple rising doses.

Secondary objectives are the exploration of pharmacokinetics (PK) following multiple oral doses.

Conditions

Diabetic Peripheral Neuropathy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Food effect

Healthy subjects receive a single dose of SYHA1402 (100mg) in either a fasted state or with a meal.

Group Type: EXPERIMENTAL

FE-SYHA1402 100mg

Intervention Type: DRUG

in either a fasted state or with a meal

Multiple doses 25mg

Healthy subjects receive multiple doses of SYHA1402 (25mg) or Placebo(25mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.

Group Type: EXPERIMENTAL

SYHA1402-25mg

Intervention Type: DRUG

SYHA1402 25mg, oral tablets

Placebo-25mg

Intervention Type: DRUG

Matching placebo tablets

Multiple doses 50mg

Healthy subjects receive multiple doses of SYHA1402 (50mg) or Placebo (50mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.

Group Type: EXPERIMENTAL

SYHA1402-50mg

Intervention Type: DRUG

SYHA1402 50mg, oral tablets

Placebo-50mg

Intervention Type: DRUG

Matching placebo tablets

Multiple doses 150mg

Healthy subjects receive multiple doses of SYHA1402 (150mg) or Placebo (150mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.

Group Type: EXPERIMENTAL

SYHA1402-150mg

Intervention Type: DRUG

SYHA1402 150mg, oral tablets

Placebo-150mg

Intervention Type: DRUG

Matching placebo tablets

Interventions

FE-SYHA1402 100mg

in either a fasted state or with a meal

Intervention Type: DRUG

SYHA1402-25mg

SYHA1402 25mg, oral tablets

Intervention Type: DRUG

Placebo-25mg

Matching placebo tablets

Intervention Type: DRUG

SYHA1402-50mg

SYHA1402 50mg, oral tablets

Intervention Type: DRUG

Placebo-50mg

Matching placebo tablets

Intervention Type: DRUG

SYHA1402-150mg

SYHA1402 150mg, oral tablets

Intervention Type: DRUG

Placebo-150mg

Matching placebo tablets

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy male or female subjects aged 18 to 45 years (inclusive).

2. Have a body mass index (BMI) between 19.0 and 26.0 kg/m2 inclusive and weigh at least 45.0 kg (female) or 50.0 kg (male) inclusive at screening.

3. With no clinically significant or relevant abnormalities as determined by medical history, vital signs, physical examination, and clinical laboratory tests.

4. All subjects of reproductive potential must agree to use effective, non-hormonal contraceptive measures (such as condoms, intrauterine devices without drugs) from the signing of informed consent to 3 months after the study. A subject is eligible to participate if she/he is not a person of childbearing potential (had a bilateral oophorectomy, bilateral salpingo-oophorectomy, or vasectomy). A male subject refrains from donating sperm during the study period and for 3 months after the study.

5. Signed informed consent form.

Exclusion Criteria

1. Female subjects who are pregnant or lactating.

2. History or current evidence of any clinically significant cardiac, endocrinologic, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic, psychiatric, renal, or other major disease, as determined by the investigator.

3. Surgery history within six months before signing the informed consent;

4. Allergic history to more than one drug or other serious allergic history.

5. Any other abnormal findings on vital signs

6. Any clinically significant abnormalities in ECG: a QTc interval greater than 450 ms (male) or 470 ms (female), or with a history of prolonged QTc interval;

7. Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (anti-HCV), Human immunodeficiency virus antibody (anti-HIV) or Treponema Pallidum antibody (Anti-TP) at screening.

8. Use of drugs within 2 weeks before signing the informed consent, including over-the-counter or prescription medication, including biological product, Chinese traditional medicine, herbal medicine, vitamin dietary supplements, health care products, oral or imbedded long-acting contraceptives.

9. Alcohol abuse or positive test for alcohol screening.

10. Smoker.

11. History or clinical evidence of drug abuse within the one years before screening, or positive test for drug abuse at screening.

12. Use of too much caffeine in beverages, foods or in any form, which may interfere the absorption, distribution, metabolism, or excretion of drugs, within 4 weeks before signing informed consent

13. Loss of blood or blood donation more than 200 mL within 8 weeks before signing informed consent, or plan on blood donation during the study period and 1 months after the last dose of drug.

14. Have a surgical schedule or a plan on excessive physical activity during the study period.

15. Subjects participating in other clinical trials, or who have participated in any other clinical trials of drugs within three months before signing informed consent;

16. Not suitable for this trial as determined by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Yanping Liu

Role: CONTACT

liuyanping@mail.ecspc.com

0311-67808817

Other Identifiers

HA1403-CSP-002；V1.0

Identifier Type: -

Identifier Source: org_study_id